Anti-VGCC negative and Anti-SOX1 positive Lambert-Eaton myasthenic syndrome as the initial presentation of small cell lung cancer: a case report - Report - MDSpire
Advertisement
Anti-VGCC negative and Anti-SOX1 positive Lambert-Eaton myasthenic syndrome as the initial presentation of small cell lung cancer: a case report
Clinical Report: Initial Presentation of Small Cell Lung Cancer as LEMS
Overview
This report details a case of a 73-year-old male with small cell lung cancer (SCLC) presenting with Lambert-Eaton myasthenic syndrome (LEMS). Notably, the patient was seropositive for anti-SOX1 antibodies and seronegative for anti-VGCC antibodies, highlighting the importance of antibody testing in atypical LEMS presentations.
Background
Lambert-Eaton myasthenic syndrome (LEMS) is a rare autoimmune disorder that can be associated with small cell lung cancer (SCLC). Approximately 50-60% of LEMS cases are paraneoplastic, with SCLC being the most common malignancy linked to this syndrome. The presence of anti-SOX1 antibodies can serve as a crucial diagnostic marker, especially in cases where anti-VGCC antibodies are absent.
Data Highlights
No numerical data or trial data presented in the article.
Key Findings
The patient was a 73-year-old male smoker diagnosed with LEMS as the initial manifestation of SCLC.
He tested positive for anti-SOX1 antibodies and negative for anti-VGCC antibodies.
Imaging revealed a left upper lobe lung mass, confirmed as SCLC, staged as T1cN3M0 (IIIB).
Following standard antitumor therapy, the patient's muscle weakness improved significantly.
The patient's overall survival has exceeded 36 months post-diagnosis.
Testing for anti-SOX1 antibodies and using the DELTA-P score are critical for malignancy screening in LEMS patients.
Clinical Implications
Healthcare professionals should consider testing for anti-SOX1 antibodies in patients presenting with LEMS, especially when anti-VGCC antibodies are negative. The DELTA-P score can aid in identifying high-risk patients for underlying malignancies, facilitating early diagnosis and treatment.
Conclusion
This case underscores the diagnostic challenges of LEMS and the importance of comprehensive antibody testing and risk assessment in patients with atypical presentations. Early detection of associated malignancies like SCLC can significantly impact patient outcomes.
